Hoth Therapeutics

HOTH

Market cap $12.4M

Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; additional endpoints demonstrated ~34% improvement in oncology toxicity (CTCAE) and ~37% reduction in patient-reported pruritus. NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced positive interim results from the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy.

Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced that the China National Intellectual Property Administration has approved issuance of a key patent covering the Company's HT-KIT cancer program, a novel therapeutic approach designed to induce apoptosis in disease-driving cells by targeting KIT signaling pathways. The patent, which originated from a PCT international application, provides important intellectual property protection in China, one of the world's largest and fastest-growing oncology markets, and further strengthens Hoth's global IP estate surrounding HT-KIT.

Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of sight to site activation and enrollment Near-term regulatory and operational catalysts Positive CTIS Conclusion Positions Company for Near-Term Clinical Trial Initiation in Cancer Patients NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European regulatory milestone for its HT-001 clinical program targeting cancer patients undergoing EGFR inhibitor therapies. The Company received a positive regulatory conclusion under the European Union Clinical Trials Information System (CTIS) for Part I.

NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics  (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies. The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients.

NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.

NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL. To learn more about NobleCon and registration to attend or scheduling a one-on-one meeting with management please visit https://nobleconference.com/ About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life.

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms. Acceptance into the NVIDIA Connect Program provides Hoth Therapeutics with access to a suite of accelerated computing resources, technical guidance, and marketing support, enabling the company to further strengthen its AI-powered research initiatives across its therapeutic pipeline.

Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a U.S. Department of Veterans Affairs (VA)–backed study evaluating the potential of glial cell line–derived neurotrophic factor (GDNF)as a novel therapy for obesity and fatty liver disease (hepatic steatosis).

>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Planned Next Steps (Near-Term): Complete GLP toxicology and CMC packages; submit IND.

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological, oncological disorders, today announced it has expanded its artificial intelligence (AI) initiative through a new NVIDIA AI Enterprise subscription license to accelerate data-driven drug development, preclinical modeling, and predictive analytics. Under the new entitlement and renewal agreement, Hoth Therapeutics has secured annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.